Alirocumab PCSK9 Inhibitors  

Praluent - SAR236553 - monoclonal antibody REGN727 - REGN727 monoclonal antibody - alirocumab      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultdeath from all causes as adverse eventserious adverse events

cardiovascular prevention  

ODYSSEY OPTIONS I   alirocumabezetimibe (on top statin)negative-100%-44%
ODYSSEY OPTIONS II   alirocumabezetimibe (on top statin)negative-100%-26%
ODYSSEY MONO      NCTalirocumabezetimibe aloneLow risk of bias negative-2%
ODYSSEY Long-Term, 2015      NCTalirocumabplacebo (on top statins)Exploratory suggesting -71%-4%
ODYSSEY Alternative      NCTalirocumabplacebo (on top statins)Low risk of bias negative19%
ODYSSEY OUTCOMES, 2018      NCTalirocumabplacebo (on top statins)Low risk of bias conclusive
ODYSSEY FH 1      NCTalirocumabplacebo (on top statins)Low risk of bias -
ODYSSEY FH 2      NCTalirocumabplacebo (on top statins)Low risk of bias -
ODYSSEY HIGH FH      NCTalirocumabplacebo (on top statins)negative-3%
ODYSSEY COMBO        NCTalirocumabplacebo (on top statins)Low risk of bias negative-49%-5%
ODYSSEY COMBO II        NCTalirocumabplacebo (on top statins)Low risk of bias negative-50%5%